Logo image of CTX.CA

CRESCITA THERAPEUTICS INC (CTX.CA) Stock Fundamental Analysis

TSX:CTX - Toronto Stock Exchange - CA2258471028 - Common Stock - Currency: CAD

0.5  +0.02 (+4.17%)

Fundamental Rating

2

Taking everything into account, CTX scores 2 out of 10 in our fundamental rating. CTX was compared to 34 industry peers in the Pharmaceuticals industry. While CTX seems to be doing ok healthwise, there are quite some concerns on its profitability. CTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year CTX has reported negative net income.
CTX had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: CTX reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: CTX reported negative operating cash flow in multiple years.
CTX.CA Yearly Net Income VS EBIT VS OCF VS FCFCTX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M -15M

1.2 Ratios

Looking at the Return On Assets, with a value of -14.05%, CTX is doing worse than 64.71% of the companies in the same industry.
CTX's Return On Equity of -20.56% is in line compared to the rest of the industry. CTX outperforms 50.00% of its industry peers.
Industry RankSector Rank
ROA -14.05%
ROE -20.56%
ROIC N/A
ROA(3y)-5.89%
ROA(5y)-4.27%
ROE(3y)-7.95%
ROE(5y)-5.81%
ROIC(3y)N/A
ROIC(5y)N/A
CTX.CA Yearly ROA, ROE, ROICCTX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

CTX has a better Gross Margin (49.36%) than 70.59% of its industry peers.
CTX's Gross Margin has declined in the last couple of years.
CTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 49.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.3%
GM growth 5Y-7.9%
CTX.CA Yearly Profit, Operating, Gross MarginsCTX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

6

2. Health

2.1 Basic Checks

CTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
CTX has less shares outstanding than it did 1 year ago.
CTX has less shares outstanding than it did 5 years ago.
CTX has a better debt/assets ratio than last year.
CTX.CA Yearly Shares OutstandingCTX.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
CTX.CA Yearly Total Debt VS Total AssetsCTX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -1.39, we must say that CTX is in the distress zone and has some risk of bankruptcy.
CTX's Altman-Z score of -1.39 is on the low side compared to the rest of the industry. CTX is outperformed by 61.76% of its industry peers.
The Debt to FCF ratio of CTX is 1.23, which is an excellent value as it means it would take CTX, only 1.23 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 1.23, CTX belongs to the top of the industry, outperforming 94.12% of the companies in the same industry.
CTX has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
CTX's Debt to Equity ratio of 0.02 is fine compared to the rest of the industry. CTX outperforms 79.41% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 1.23
Altman-Z -1.39
ROIC/WACCN/A
WACC8.43%
CTX.CA Yearly LT Debt VS Equity VS FCFCTX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

CTX has a Current Ratio of 2.36. This indicates that CTX is financially healthy and has no problem in meeting its short term obligations.
CTX has a Current ratio (2.36) which is comparable to the rest of the industry.
CTX has a Quick Ratio of 1.59. This is a normal value and indicates that CTX is financially healthy and should not expect problems in meeting its short term obligations.
CTX has a better Quick ratio (1.59) than 61.76% of its industry peers.
Industry RankSector Rank
Current Ratio 2.36
Quick Ratio 1.59
CTX.CA Yearly Current Assets VS Current LiabilitesCTX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

0

3. Growth

3.1 Past

CTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -45.11%.
CTX shows a small growth in Revenue. In the last year, the Revenue has grown by 1.17%.
Measured over the past years, CTX shows a decrease in Revenue. The Revenue has been decreasing by -2.60% on average per year.
EPS 1Y (TTM)-45.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-53.12%
Revenue 1Y (TTM)1.17%
Revenue growth 3Y5.3%
Revenue growth 5Y-2.6%
Sales Q2Q%-29.2%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CTX.CA Yearly Revenue VS EstimatesCTX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CTX.CA Price Earnings VS Forward Price EarningsCTX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, CTX is valued a bit cheaper than the industry average as 70.59% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 16.3
EV/EBITDA N/A
CTX.CA Per share dataCTX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CRESCITA THERAPEUTICS INC

TSX:CTX (6/11/2025, 7:00:00 PM)

0.5

+0.02 (+4.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-14 2025-05-14
Earnings (Next)08-05 2025-08-05
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners12.27%
Ins Owner ChangeN/A
Market Cap9.51M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.52
P/FCF 16.3
P/OCF 5.18
P/B 0.64
P/tB 0.72
EV/EBITDA N/A
EPS(TTM)-0.16
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.03
FCFY6.13%
OCF(TTM)0.1
OCFY19.3%
SpS0.95
BVpS0.78
TBVpS0.7
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.05%
ROE -20.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 49.36%
FCFM 3.22%
ROA(3y)-5.89%
ROA(5y)-4.27%
ROE(3y)-7.95%
ROE(5y)-5.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.3%
GM growth 5Y-7.9%
F-Score5
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 1.23
Debt/EBITDA N/A
Cap/Depr 93.78%
Cap/Sales 6.9%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.36
Quick Ratio 1.59
Altman-Z -1.39
F-Score5
WACC8.43%
ROIC/WACCN/A
Cap/Depr(3y)37.08%
Cap/Depr(5y)28.12%
Cap/Sales(3y)2.6%
Cap/Sales(5y)2.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-45.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-53.12%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)1.17%
Revenue growth 3Y5.3%
Revenue growth 5Y-2.6%
Sales Q2Q%-29.2%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-52.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y115.93%
FCF growth 3YN/A
FCF growth 5Y-21.27%
OCF growth 1Y307.56%
OCF growth 3YN/A
OCF growth 5Y-12.49%